Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada

Transfusion and Apheresis Science

Volumn 51, Issue 1, 2014, Pages 25-34

  Huisman, Eline L ^a   van Eerd, Margreet C ^a   Ouwens, J N Mario ^a   de Peuter, Maria A ^a  

^a MAPI GROUP   (Netherlands)

Author keywords

Canada; Cost effectiveness analysis; Fresh frozen plasma; OctaplasLG ; Transfusion

Indexed keywords

DETERGENT; FRESH FROZEN PLASMA; OCTAPLAS; SOLVENT;

ALLERGIC REACTION; ARTICLE; BUDGET; CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; QUALITY OF LIFE; ADULT; BLOOD COMPONENT THERAPY; COST; FEMALE; MALE; MIDDLE AGED; STATISTICAL MODEL;

ADULT; BLOOD COMPONENT TRANSFUSION; CANADA; COSTS AND COST ANALYSIS; DETERGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; SOLVENTS;

EID: 84930042362     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.04.045     Document Type: Article

References (42)

1. Solheim B.G., Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006, 35(1):83-90.
2. Riedler G.F., Haycox A.R., Duggan A.K., Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003, 85(2):88-95.
3. Kleinman S., Cameron C., Custer B., Busch M., Katz L., Kralj B., et al. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010, 50(12):2592-2606.
4. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39(1):75-82.
5. Krusius T., Auvinen M.K., Nikkinen L. Introduction of Octaplas in clinical use decreased the rate of severe adverse reactions. Vox Sang 2010, 99:461. [P-1018].
6. Heger A., Bailey A., Neisser-Svae A., Ertl M., Romisch J., Svae T.E. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG(R) manufacturing - results from animal bioassay studies. Vox Sang 2012, 102(4):294-301.
7. Neisser-Svae A., Bailey A., Gregori L., Heger A., Jordan S., Behizad M., et al. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG. Vox Sang 2009, 97(3):226-233.
8. Svae TE, Heger A, Biesert L, Neisser-Svae A, Frenzel W. Solvent/Detergent Plasma. In: Bertolini J, Goss N, Curling J, editors. Production of Plasma Proteins for Therapeutic Use, Hoboken, NJ, USA: John Wiley & Sons, Inc. 2013. pp. 345-57.
9. Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. Canadian Agency for Drugs and Technologies in Health. <> April 2009. http://www.cadth.ca/media/pdf/I4002_Octaplas%20versus%20FFP_L4_e_April%202009.pdf.
10. ®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. Transfus Apher Sci 2010 Dec, 43(3):251-259.
11. Life expectancy Canada. <> 2002. http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm.
12. ISPOR. Pharmacoeconomic Guidelines Around the World. <> 2010. http://www.ispor.org/PEguidelines/countrydet.asp?c=21&t=1.
13. Vaara I., Nilsson C.D. SD plasma safer than fresh-frozen plasma. Comparative studies show advantages of industrially produced plasma. Lakartidningen 2010, 107(3):106-107.
14. Ontario Case Costing Initiative. <> 2012. http://www.occp.com/mainPage.htm.
15. Bank of Canada. Canadian Consumer Price Index. <> 2012. http://www.bankofcanada.ca/rates/price-indexes/cpi/.
16. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999, 39(5):479-487.
17. Octaplas Compared to Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: Supplementary Analyses Relating to Risk of Infection from an Unknown Virus. Canadian Agency for Drugs and Technologies in Health. <> 2009. http://www.cadth.ca/media/pdf/htis/L0073%20Octaplas%20Update%20final.pdf.
18. Reutter J.C., Sanders K.F., Brecher M.E., Jones H.G., Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001, 16(3):134-138.
19. Custer B., Hoch J.S. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009, 23(1):1-2.
20. Eder A.F., Herron R.M., Strupp A., Dy B., White J., Notari E.P., et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010, 50(8):1732-1742.
21. Tabor E., Epstein J.S. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002, 42(9):1230-1237.
22. Stramer S.R. Impact of NAT on serological screening of transfusion-transmitted agents. ISBT Sci Series 2006, 1:194-202.
23. Cohen B.J., Buckley M.M. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988, 25(2):151-153.
24. Svae T.E., Neisser-Svae A., Bailey A., Reichl H., Biesert L., Schmidt T., et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008, 39(1):59-67.
25. Paul-Ehrlich-Institut. Hamovigilanzdaten von 1997 bis 2008. <> 2012. http://www.pei.de/hv-bericht.
26. Bauch C.T., Anonychuk A.M., Pham B.Z., Gilca V., Duval B., Krahn M.D. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007, 25(51):8536-8548.
27. Kleinman S., Chan P., Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17(2):120-162.
28. Kanwal F., Farid M., Martin P., Chen G., Gralnek I.M., Dulai G.S., et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006, 101(9):2076-2089.
29. El Saadany S., Coyle D., Giulivi A., Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005, 6(2):159-165.
30. Chancellor J.V., Hill A.M., Sabin C.A., Simpson K.N., Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997, 12(1):54-66.
31. Phillips of Worth Matravers L, Bridgeman J, Ferguson-Smith M. The inquiry into BSE variant CJD in the United Kingdom; 2000.
32. Taylor C, Asher D, Davies T, Milkins C, et al. On behalf of the Serious Hazards of Transfusion (SHOT) steering group. The 2008 Annual SHOT report; 2009.
33. Taylor C, Cohen H, Jones H, et al. On behalf of the Serious Hazards of Transfusion (SHOT) steering group. The 2007 Annual SHOT report; 2008.
34. Taylor C, Cohen H, Mold D, Jones H, et al. On behalf of the Serious Hazards of Transfusion (SHOT) steering group. The 2009 Annual SHOT report; 2010.
35. Angus D.C., Musthafa A.A., Clermont G., Griffin M.F., Linde-Zwirble W.T., Dremsizov T.T., et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163(6):1389-1394.
36. Levy A.R., Kowdley K.V., Iloeje U., Tafesse E., Mukherjee J., Gish R., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008, 11(3):527-538.
37. Gagnon Y.M., Levy A.R., Iloeje U.H., Briggs A.H. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004, 38(10 Suppl. 3):S179-S186.
38. Chong C.A., Gulamhussein A., Heathcote E.J., Lilly L., Sherman M., Naglie G., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98(3):630-638.
39. Wong J.B., Bennett W.G., Koff R.S., Pauker S.G. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998, 280(24):2088-2093.
40. Simpson K.N., Roberts G., Hicks C.B., Finnern H.W. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials 2008, 9(4):225-237.
41. Krentz H.B., Auld M.C., Gill M.J. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003, 169(2):106-110.
42. Philip Jacobs JB. An Alberta standard cost list for health economics evaluations. <> 1997. http://www.ihe.ca/documents/1997-05paper.pdf.